Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 2/20 | 0.41 |
| ▸ | KLK14 | Q9P0G3 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7791033 | 0.84 | ADORA2A (0.61) | WHR1EGFRKITMEN1KMT2A | |
| SCHEMBL27117037 | 0.80 | WHR1 (0.71) | WHR1EGFRKDRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3774502 | 0.77 | LMNA (0.48) | SMN1; SMN2ALDH1A1KMT2ALMNATP53 | |
| SCHEMBL6667126 | 0.77 | PDGFRB (0.56) | WHR1EGFRKDRKITSMN1; SMN2 | |
| SCHEMBL27117048 | 0.77 | PDGFRB (0.47) | WHR1EGFRKDRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3772243 | 0.76 | ADORA2A (0.66) | ALDH1A1LMNAPOLBMAPT | |
| SCHEMBL1941112 | 0.76 | WHR1 (0.60) | WHR1EGFRKDRSMN1; SMN2ALDH1A1 | |
| SCHEMBL1942856 | 0.75 | WHR1 (0.56) | WHR1EGFRKDRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4404867 | 0.75 | KDM4E (0.60) | WHR1ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL7799239 | 0.74 | ADORA2A (0.51) | WHR1EGFRKITMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PDE5A, PDE12, PDE2A | WHR1 1618/4885EGFR 4837/4885KDR 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.